Abstract:Since the recent clinical approval of siRNA-based drugs and COVID-19 mRNA vaccines, the potential of RNA therapeutics for patient healthcare has become widely accepted. Lipid nanoparticles (LNPs) are currently the most advanced nanocarriers for RNA packaging and delivery. Nevertheless, the intracellular delivery efficiency of state-of-the-art LNPs remains relatively low and safety and immunogenicity concerns with synthetic lipid components persist, altogether rationalizing the exploration of alternative LNP compositions. In addition, there is an interest in exploiting LNP technology for simultaneous encapsulation of small molecule drugs and RNA in a single nanocarrier. Here, we describe how well-known tricyclic cationic amphiphilic drugs (CADs) can be repurposed as both structural and functional components of lipid-based NPs for mRNA formulation, further referred to as CADosomes. We demonstrate that selected CADs, such as tricyclic antidepressants and antihistamines, self-assemble with the widely-used helper lipid DOPE to form cationic lipid vesicles for subsequent mRNA complexation and delivery, without the need for prior lipophilic derivatization. Selected CADosomes enabled efficient mRNA delivery in various in vitro cell models, including easy-to-transfect cancer cells (e.g. human cervical carcinoma HeLa cell line) as well as hard-to-transfect primary cells (e.g. primary bovine corneal epithelial cells), outperforming commercially available cationic liposomes and state-of-the-art LNPs. In addition, using the antidepressant nortriptyline as a model compound, we show that CADs can maintain their pharmacological activity upon CADosome incorporation. Furthermore, in vivo proof-of-concept was obtained, demonstrating CADosome-mediated mRNA delivery in the corneal epithelial cells of rabbit eyes, which could pave the way for future applications in ophthalmology. Based on our results, the co-formulation of CADs, helper lipids and mRNA into lipid-based nanocarriers is proposed as a versatile and straightforward approach for the rational development of drug combination therapies.

Intranasal Delivery and Transfection of mRNA Therapeutics in the Brain Using Cationic Liposomes.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration

Ddel-01. Engineering Mrna Therapies For Brain Tumors

Lipid Nanoparticles Deliver mRNA to the Brain after an Intracerebral Injection

Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain

Intracranial Delivery of Synthetic Mrna to Suppress Glioblastoma

Engineering Brain-Derived Neurotrophic Factor Mrna Delivery for the Treatment of Alzheimer’s Disease

A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy

Lipid Nanoparticle-Mediated Delivery of mRNA Into the Mouse and Human Retina and Other Ocular Tissues

Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection

Branched‐Tail Lipid Nanoparticles for Intravenous mRNA Delivery to Lung Immune, Endothelial, and Alveolar Cells in Mice

A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery

Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease

Brain-targeted intranasal delivery of protein-based gene therapy for treatment of ischemic stroke

Efficient Delivery of Mrna Using Crosslinked Nucleic Acid Nanogel As a Carrier

Brain gene therapy with Trojan horse lipid nanoparticles

Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice.

Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles

Synthesis and Characterization of Fatty Acid Grafted Chitosan Polymeric Micelles for Improved Gene Delivery of VGF to the Brain through Intranasal Route

Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments

A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs